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Essentials
• peroxisome proliferator-activated receptor c (PPARc)
agonists inhibit platelet function.
• PPARc agonists negatively regulate outside-in signaling
via integrin aIIbb3.
• PPARc agonists disrupt the interaction of Ga13 with
integrin b3.
• This is attributed to an upregulation of protein kinase
A activity.
Summary. Background: Agonists for the peroxisome pro-
liferator-activated receptor (PPARc) have been shown to
have inhibitory effects on platelet activity following stim-
ulation by GPVI and GPCR agonists. Objectives: Pro-
found effects on thrombus formation led us to suspect a
role for PPARc agonists in the regulation of integrin
aIIbb3 mediated signaling. Both GPVI and GPCR signal-
ing pathways lead to aIIbb3 activation, and signaling
through aIIbb3 plays a critical role in platelet function
and normal hemostasis. Methods: The effects of PPARc
agonists on the regulation of aIIbb3 outside-in signaling
was determined by monitoring the ability of platelets to
adhere and spread on fibrinogen and undergo clot retrac-
tion. Effects on signaling components downstream of
aIIbb3 activation were also determined following adhe-
sion to fibrinogen by Western blotting. Results: Treat-
ment of platelets with PPARc agonists inhibited platelet
adhesion and spreading on fibrinogen and diminished clot
retraction. A reduction in phosphorylation of several
components of aIIbb3 signaling, including the integrin b3
subunit, Syk, PLCc2, focal adhesion kinase (FAK) and
Akt, was also observed as a result of reduced interaction
of the integrin b3 subunit with Ga13. Studies of VASP
phosphorylation revealed that this was because of an
increase in PKA activity following treatment with PPARc
receptor agonists. Conclusions: This study provides fur-
ther evidence for antiplatelet actions of PPARc agonists,
identifies a negative regulatory role for PPARc agonists
in the control of integrin aIIbb3 outside-in signaling, and
provides a molecular basis by which the PPARc agonists
negatively regulate platelet activation and thrombus for-
mation.
Keywords: blood platelets; platelet activation; platelet
glycoprotein GPIIb-IIIa complex; PPAR gamma; protein
kinase A.
Introduction
Platelets play a vital role in the prevention of blood loss
following vascular injury. Through a balance of inhibitory
and activating signals, circulating platelets are maintained
in a quiescent state in the undamaged circulation and are
only activated when signals such as exposed subendothe-
lial matrix proteins at sites of vascular injury outweigh
endogenous inhibitory signaling. Platelets adhere rapidly
to the site of injury and become activated, characterized
by granule secretion, formation of thromboxane A2 and
activation of integrin aIIbb3, which is converted from a
low to a high-affinity conformation, enabling it to bind to
fibrinogen and von Willebrand factor (VWF). This initial
activation is followed by platelet shape change and aggre-
gation that is supported by fibrinogen binding to the
high-affinity integrin aIIbb3. Formation of a fibrin coat
and clot retraction, which is driven through integrin
aIIbb3-stimulated outside-in signaling, then stabilizes the
growing thrombus [1].
Inhibitory mechanisms are essential for preventing the
formation of unwanted thrombi and for limiting thrombus
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growth and size. Platelets are inhibited through a number
of endogenous mechanisms, including by nitric oxide and
prostacyclin released from the healthy endothelium [2] and
via signaling receptors on the cell surface such as PECAM-
1 and G6b [3–5]. A recently identified class of intracellular
inhibitory receptors is nuclear receptors. Usually involved
in the regulation of the transcription of genes, several
nuclear receptors have been identified in human platelets
and have been shown to play a role in the regulation of pla-
telet activity [2,3,6–10]. One such receptor is the peroxi-
some proliferator-activated receptor-c (PPARc), a member
of the nuclear hormone superfamily [8,10]. In nucleated
cells, the PPARc receptor is known to function in the regu-
lation of many metabolic pathways, including lipid and
glucose metabolism and homeostasis [11–13]. Recent stud-
ies suggest that the actions of nuclear receptors are not
restricted to gene transcription because increasing evidence
supports non-genomic actions of these receptors [14,15].
Studies using platelets support non-genomic roles for the
PPARc receptor [7,9,12,16,17]. Agonists for PPARc, such
as thiazolidinediones that are in use as a treatment for type
2 diabetes mellitus, have been shown to have inhibitory
effects on platelet signaling and activation [6–8,18,19],
which could underlie the reported reduction in atheroscle-
rosis, reduced inflammation and cardio-protective effects
in patients treated with PPARc agonists [12,13,16,20–24].
We have previously observed the ability of PPARc ago-
nists to interfere with GPVI-proximal signaling, but this
cannot explain the PPARc agonist-dependent inhibition
observed following stimulation of platelets with thrombin
and other GPCR agonists. Because the integrin aIIbb3
outside-in signaling pathway shares several components
with the GPVI signaling pathway [25], and is essential for
GPCR-induced platelet activation, we investigated
whether the PPARc receptor is involved in the regulation
of integrin aIIbb3 signaling and the mechanisms by which
its agonists negatively regulate platelet function.
The results described here support a role for PPARc in
the negative regulation of integrin aIIbb3 outside-in signal-
ing through the up-regulation of PKA activity and subse-
quent inhibition of phosphorylation of b3 and downstream
components of the integrin aIIbb3 signaling pathway.
Materials and methods
Reagents
Fibrinogen, bovine thrombin, H89, GW9662 and IMBX
were purchased from Sigma Aldrich (Poole, UK).
15dPGJ2 was purchased from Enzo Life Sciences and
Ciglitazone and SQ22536 from Tocris Bioscience (Bristol,
UK). The cAMP ELISA kit was from Enzo Life Sciences
(Exeter, UK). Primary anti- FAK (focal adhesion kinase)
(C20), Syk (N-19), PLCc2 (Q20), b3 (C20) and actin
(C11) antibodies were purchased from Santa Cruz Biotech-
nology (Heidelberg, Germany). Phospho-specific primary
antibodies for b3 Y779 and Akt S473 were from Abcam
(Cambridge, UK). Anti-phospho–PKC (protein kinase C)
substrate, phospho-S157 and S239 VASP and phospho-Ser
19 myosin light chain antibodies were purchased from New
England BioLabs (Cell Signalling, Hitchin, UK), and anti-
phospho-Tyr 4G10 antibody was purchased from Milli-
pore (Watford, UK). Fluorophore conjugated secondary
antibodies, Fluo-4 calcium indicator dye and Alexa-488
and Alexa-647 conjugated phalloidin were purchased from
Life Technologies (Paisely, UK). All other reagents were
from previously described sources [26].
Human washed platelet preparation
Human blood was obtained from consenting aspirin-free
healthy volunteers, in accordance with the procedures
approved by the University of Reading Research Ethics
Committee. Blood was collected into 4% (w/v) sodium
citrate before mixing with acid citrate dextrose (29.9 mM
Na3C6H5O7, 113.8 mM glucose, 72.6 mM NaCl and 2.9 mM
citric acid [pH 6.4]). Washed platelets were prepared by
centrifugation at 100 9 g for 20 min, followed by centrifu-
gation twice at 1000 9 g for 10 min in the presence of
1.25 lg mL1 prostacyclin (PGI2) as described previously
[27]. Platelets were resuspended in modified Tyrode’s-
HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM
KCl, 12 mM NaHCO3, 20 mM N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid, 5 mM glucose and 1 mM
MgCl2, pH 7.3) and rested for 30 min at 30 °C before use.
Spreading on fibrinogen
Washed platelets (2 9 107 mL1), pretreated with PPARc
agonists or vehicle control (0.1% v/v dimethylsulfoxide
[DMSO]), were exposed to fibrinogen (100 lg mL1)
coated coverslips (blocked with 1% bovine serum albu-
min [BSA]) and incubated for 45 min at 37 °C. Non-
adherent platelets were removed and coverslips washed
with phosphate buffered saline (PBS) before fixing using
0.2% (v/v) paraformaldehyde solution. Platelets were per-
meabilised in 0.1% (v/v) Triton-X100 prior to staining
with Alexa 488 conjugated-phalloidin for 1 h. Adherent
platelets were then imaged with a 100x magnification oil
immersion lens on a Nikon A1-R confocal microscope.
Adhesion and spreading data in each experiment were
measured by counting the number of platelets and the
extent of spreading in five fields of view chosen randomly
from each sample.
Clot retraction assay
Human washed platelets at 5 9 108 mL1 were added to
aggregometer tubes in the presence of 2 mg mL1 fibrino-
gen and 2 mM CaCl2 and preincubated with 15dPGJ2 or
vehicle control (0.1% v/v DMSO). Clot retraction was
initiated by adding an equal volume of 2 U mL1
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thrombin and left for 1 h at room temperature before the
weight of the clot was measured.
Adhesion on collagen under flow
Adhesion on collagen in the presence of integrillin (10 lM)
was studied in vitro using microfluidic flow cells (Vena8,
Cellix Ltd, Dublin, Ireland) as described previously [28].
DiOC6 loaded human whole blood with or without treat-
ment, in the presence of integrillin (10 lM), was perfused
through collagen-coated (100 lg mL1) Vena8Biochips at
a shear rate of 20 dyn cm2. Platelet adhesion was deter-
mined by comparing fluorescence intensity in the vehicle
and treated samples.
Immunoblotting and immunoprecipitation
Following adhesion to fibrinogen or stimulation with
thrombin (0.1 U mL1) for 5 min under non-stirring con-
ditions, washed platelets (4 9 108 cells mL1) were lysed
in an equal volume of NP40 buffer (300 mM NaCl, 20 mM
Tris base, 2 mM EGTA, 2 mM EDTA, 1 mM PMSF,
10 lg mL1 aprotinin, 10 lg mL1 leupeptin, 0.7 lg
mL1 pepstatin A, 2 mM sodium orthovanadate, 2% (v/v)
NP-40, pH 7.3) and proteins of interest isolated by
immunoprecipitation using 1 lg mL1 of appropriate
antibodies. Prior to immunoblotting, which was per-
formed as described previously [7], the lysates of adhered
washed platelets were corrected for the level of adhesion
by determining the protein concentration of each sample.
Proteins were detected using fluorophore-conjugated sec-
ondary antibodies and visualized using a Typhoon FLA
9500 Fluorimager and Image Quant software (GE Health-
care, Chalfont, Buckinghamshire, UK). Band intensities
were quantified and levels of the immunoprecipitated
protein or loading control were measured and used to nor-
malize the phosphorylation data for protein loading levels.
Statistical analysis
Statistical analyses were performed on data using Graph-
Pad prism software (GraphPad Software, San Diego, CA,
USA). Data were analyzed using Student’s t-test and one-
way analysis of variance (ANOVA). Values obtained in sev-
eral experiments were converted into percentages for com-
parison of controls with treated samples. P ≤ 0.05 was
considered statistically significant. Unless stated otherwise,
values are expressed as mean  SEM; n values are ≥ 3.
Results
PPARc agonists negatively regulate adhesion and spreading
on fibrinogen
Following fibrinogen binding and clustering of integrin
aIIbb3, outside-in signaling is initiated, leading to platelet
shape change and spreading. To determine whether the
PPARc receptor plays a role in the regulation of out-
side-in signaling through integrin aIIbb3, adhesion and
spreading on fibrinogen (100 lg mL1) were analyzed in
the presence and absence of PPARc receptor agonists.
Additional platelet agonists were not added, to enable
the study to focus (primarily) on outside-in signaling
through aIIbb3. As shown in Fig. 1, treatment of plate-
lets with increasing concentrations of the endogenous
PPARc agonist 15dPGJ2 caused a significant decrease
in the ability of the platelets to adhere to and spread
on fibrinogen when compared with vehicle-treated con-
trols. 15dPGJ2 (20 lM) caused ~ 50% inhibition of
adhesion and a significant reduction in spreading. A
reduction in surface area coverage was observed follow-
ing treatment with increasing concentrations of 15dPGJ2
(data not shown) and ~50% fewer platelets generated
lamellipodia compared with vehicle control (0.1% v/v
DMSO). Inhibition of both adhesion and spreading was
also observed in the presence of inhibitors of ADP and
thromboxane A2 (Figure S1A), which is in agreement
with previously published data showing PPARc agonist-
induced inhibition of aggregation is independent of reg-
ulation of the release of secondary mediators [7].
Longer time-courses for adhesion and spreading were
also studied, to test whether the defect in spreading was
a result of reduced adhesion kinetics. As shown in Fig-
ure S1(B), a delay in platelet adhesion kinetics is
observed following treatment with 15dPGJ2, where after
90 min the number of adhered platelets treated with
15dPGJ2 was similar to the number of vehicle-treated
platelets adhered at 45 min. Treatment of platelets with
two alternative synthetic PPARc agonists, ciglitazone
and rosiglitazone (20 lM), both thiazolidinediones, also
caused inhibition of both adhesion and spreading on
fibrinogen compared with the untreated control (Fig-
ure S2). In contrast to the PPARc agonists 15dPGJ2
and Ciglitazone, the PPARc antagonist GW9662
(10 lM) did not alter platelet adhesion or spreading on
fibrinogen under static conditions compared with vehicle
control (Figure S2C).
15dPGJ2 inhibits platelet clot retraction
Outside-in aIIbb3 signaling is essential for the process of
clot retraction that is required for thrombus stabiliza-
tion. As our studies of adhesion and spreading indicate
a role in integrin aIIbb3 outside-in signaling, the effect
of 15dPGJ2 (Fig. 1B), ciglitazone and rosiglitazone (Fig-
ure S2Aiv, Biv) on clot retraction was explored. Pre-
incubation of platelets with all three PPARc ligands
resulted in an increase in clot weight and therefore an
inhibition of clot retraction after 90 minutes, compared
with vehicle control (0.1% v/v DMSO). These results
support a negative regulatory role for the PPARc recep-
tor agonists in outside-in signaling mediated via integrin
aIIbb3.
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PPARc agonists do not alter adhesion to collagen under flow
It has been previously described that treatment of plate-
lets with PPARc agonists results in a significant inhibi-
tion of thrombus formation on collagen under flow
conditions [7]. As we have shown that PPARc agonists
inhibit integrin aIIbb3 outside-in signaling, we sought to
determine whether this previously observed reduction in
thrombus formation on collagen could be attributed to
impaired aIIbb3 signaling and thrombus instability rather
than to reduced adhesion to collagen. Platelets were trea-
ted with integrillin, an antagonist of integrin aIIbb3, to
prevent fibrinogen binding, outside-in signaling and plate-
let aggregation, and the ability of platelets to adhere to
collagen under arterial flow was determined. As shown in
Fig. 1(C), no difference in adhesion to collagen (mea-
sured as overall fluorescence) was observed in 15dPGJ2-
treated whole blood compared with vehicle control (0.1%
v/v DMSO) in the presence of integrillin, suggesting that
the early stages of thrombus formation (adhesion) on
collagen are unaffected. In contrast, adhesion to fibrino-
gen under flow was reduced following treatment with
15dPGJ2 (Fig. 1D), further supporting a role for
15dPGJ2 in the negative regulation of outside-in signal-
ing in vitro. We therefore hypothesize that the previously
described inhibition of thrombus formation [7] is a result
of a reduction in integrin function and outside-in
signaling.
PPARc agonists reduce myosin light chain phosphorylation
Integrin aIIb3 outside-in signaling driven platelet shape
change and spreading requires cytoskeletal remodeling. A
major regulator of this process is myosin IIa. Phosphory-
lation of the myosin light chain on serine 19 downstream
of RhoA enables the interaction of myosin with actin fila-
ments, a process essential for shape change and platelet
spreading. We therefore asked whether phosphorylation
and activation of the myosin light chain is altered in pla-
telets following treatment with agonists for PPARc.
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Fig. 1. The effect of the peroxisome proliferator-activated receptor c (PPARc) agonists on outside-in signaling. Human washed platelets pre-
treated for 10 min with or without increasing concentrations of 15dPGJ2 (1, 5, 10 and 20 lM) or vehicle control were exposed to fibrinogen
(100 lg mL1)-coated coverslips. (A) (i) Representative images of spreading and adhesion after 45 min in vehicle and treated samples. Platelets
were stained with phalloidin Alexa-488 for visualization. Images were taken under oil immersion with magnification 9 100. (ii) Adhesion: num-
ber of platelets adhered were counted in five randomly selected fields of view for each experiment and the number of cells adhered expressed as
a percentage of the vehicle treated control. (iii) Spreading: platelets were classified into three different categories to determine the extent of their
spreading (Adhered but not spread. Filopodia: platelets in the process of extending filopodia. Lamellipodia: platelets in the process of extending
lamellipodia, including those fully spread). At least 100 platelets of each type were scored. Results expressed as relative frequency, as a percent-
age of the total number of platelets adhered. (B) Clot retraction. Human washed platelets pretreated for 10 min with or without increasing con-
centrations of 15dPGJ2 (5, 10 and 20 lM) or vehicle control were added to aggregometer tubes in the presence of 2 mg mL1 fibrinogen and
2 mM CaCl2. Clot retraction was initiated by adding 1 U mL
1 thrombin and left to proceed for 1 h at room temperature. Clot retraction was
determined by weighing the clot. (i) Representative images using red blood cell stained platelet rich plasma (shown). (ii) Data expressed as per-
centage of vehicle treated control. (C and D) DiOC6 loaded human whole blood was pretreated with vehicle (circles) or 20 lM 15dPGJ2 (trian-
gles) in the presence of integrillin (10 lM) to prevent platelet aggregation for 5 min before (C) perfusion through collagen-coated
(100 lg mL1) Vena8Biochips or (D) perfusion through fibrinogen-coated (100 lg mL1) Vena8Biochips at a shear rate of 20 dyn cm2. Plate-
let adhesion and surface area coverage were determined after 5 min by comparing fluorescence intensity in the vehicle and treated samples.
Unless stated otherwise, results represent mean + SEM for n ≥ 3. *Indicates P ≤ 0.05 in comparison with vehicle controls.
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Pretreatment of human washed platelets with 15dPGJ2
(10, 20 lM) caused a significant reduction in myosin light
chain phosphorylation compared with vehicle control
(0.1% v/v DMSO) in both thrombin (0.1 U mL1)-stimu-
lated and fibrinogen (100 lg mL1)-adhered platelets
(Fig. 2). Similar results in thrombin-stimulated platelets
were also achieved following treatment with ciglitazone
(20 lM) (Figure S3A). This suggests that PPARc agonists
may act to negatively regulate the components of the inte-
grin aIIbb3 signaling pathway.
PPARc agonist 15dPGJ2 inhibits phosphorylation of integrin
b3 and downstream signaling
Phosphorylation of integrin b3 at Y773 (Y747 in mice) is
essential for outside-in signaling by aIIbb3 [29–32]
because phosphorylation at this site is required for the
dissociation of talin and association of Ga13, which
enables a ‘switch’ from inside-out to outside-in signaling
[33,34]. The effect of 15dPGJ2 and ciglitazone on phos-
phorylation of b3 at Y773 was determined in fibrinogen
(100 lg mL1)-adhered platelets. The number of adhered
platelets was normalized to ensure any alterations in
phosphorylation were not a result of altered adhesion.
Adhesion to fibrinogen was associated with an increase in
phosphorylation of b3 and, as shown in Fig. 3(A) and
Figure S3(B), treatment with either 20 lM 15dPGJ2 or
ciglitazone caused a reduction of ~50% and ~30%,
respectively, in b3 Y773 phosphorylation in comparison
with vehicle control-treated platelets.
This reduction in b3 phosphorylation may alter the
ability of aIIbb3 to bind to fibrinogen and propagate
outside-in signaling, as previously published data show
that PPARc agonists reduce fibrinogen binding in ago-
nist-stimulated platelets [7] but may also prevent out-
side-in signal transduction following fibrinogen binding
to the integrin. In support of the latter a significant
reduction (~50%) in both Syk and PLCc2 phosphoryla-
tion (Fig. 3B) was observed in fibrinogen-adhered
washed platelet lysates treated with the PPARc agonist.
Protein kinase C (PKC) is a key mediator of down-
stream signaling events and its activity is regulated by
intracellular calcium levels and production of diacylglyc-
erol. Consistent with the inhibition of PLCc2, analysis
of levels of PKC substrate phosphorylation, a marker
of PKC activity, showed a reduction in phosphorylation
of approximately 25% in fibrinogen-adhered platelets
that had been pretreated with 15dPGJ2 compared with
vehicle controls (Fig. 3C). A similar reduction in
the level of PKC substrate phosphorylation was
observed following treatment with ciglitazone (data not
shown), supporting that these ligands act through
PPARc to negatively regulate integrin aIIbb3 outside-in
signaling.
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Fig. 2. The effect of 15dPGJ2 on phosphorylation of the myosin light chain. Effect of the peroxisome proliferator-activated receptor c
(PPARc) agonist 15dPGJ2 (0, 10, 20 lM) on the phosphorylation of the myosin light chain at Ser19 was determined using (A) thrombin-stimu-
lated (0.1 U mL1) and (B) fibrinogen-adhered (100 lg mL1) human washed platelets. Platelet lysates were examined by immunoblot analysis
using a myosin light chain phospho-site-specific antibody for S19. Blots were reprobed for total actin to control for protein loading. (i) Repre-
sentative blots shown. (ii) Levels of phosphorylation were quantified and expressed as a percentage of vehicle treated controls. Results represent
mean + SEM for n ≥ 3. *Indicates P < 0.05 in comparison with vehicle controls.
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PPARc agonist-treated platelets show reduced focal
adhesion kinase phosphorylation
A key step in the second wave of cytoskeletal rearrange-
ments following the release of ADP and secondary media-
tors, is the phosphorylation and activation of focal
adhesion kinase (FAK) and PI3-kinases, which are essen-
tial for platelet spreading [35–39]. Treatment of platelets
with the PPARc agonist 15dPGJ2 caused a 50% reduc-
tion in phosphorylation of FAK in comparison with con-
trols (Fig. 3D), which is consistent with the ability of the
PPARc agonists to inhibit b3 phosphorylation and plate-
let shape change and spreading. The effect of 15dPGJ2
on Akt phosphorylation, a key downstream effector of
PI3K, was also determined. As shown in Fig. 3(D), fib-
rinogen-adhered human washed platelets pretreated with
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Fig. 3. The effect of the peroxisome proliferator-activated receptor c (PPARc) agonist 15dPGJ2 on phosphorylation of integrin b3 signaling
components. 15dPGJ2-treated (0, 10 and 20 lM) human washed platelet lysates were tested for phosphorylation of (A) the integrin b3 tail at
Y773, (B) Syk and PLCc2 phosphorylation, (C) protein kinase C (PKC) substrate phosphorylation and (D) focal adhesion kinase (FAK) and
Akt phosphorylation. 15dPGJ2 or vehicle treated platelets were adhered to fibrinogen, lysed in SDS PAGE Laemmli sample buffer, separated
on SDS PAGE gels and transferred to poly(vinylidene difluoride) (PVDF) membranes before immunoblotting with a b3 phospho-site-specific
antibody for Y773, a phospho-site-specific antibody for the PKC substrate recognition sequence and an Akt phospho-site-specific antibody for
S473. Syk, PLCc2 and FAK were immunoprecipitated from lysates prior to addition of laemmli sample buffer and phosphorylation detected
using 4G10 antibody. Blots were reprobed for total b3, Syk, PLCc2 or actin to confirm equal loading. (i) Representative blots shown. (ii)
Levels of phosphorylation were quantified and expressed as a percentage of vehicle treated controls. Results represent mean + SEM for n ≥ 3.
*Indicates P < 0.05 in comparison with vehicle controls.
© 2016 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
PPARc negatively regulates outside-in signaling 361
15dPGJ2 displayed decreased levels of Akt Ser473 phos-
phorylation, with ~70% inhibition following treatment
with 20 lM 15dPGJ2 in comparison with vehicle-treated
controls. These observations further support a negative
role for the PPARc agonists in the regulation of aIIbb3
outside-in signaling.
PPARc agonists up-regulate PKA but not PKG activity
Negative regulators of platelet activation can function
either by reducing positive signaling or by increasing inhi-
bitory signaling. The cyclic nucleotides cAMP and cGMP,
through activation of adenylyl cyclase and cyclic AMP-
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dependent protein kinase (PKA) and soluble guanylyl
cyclase and cyclic GMP-dependent protein kinase (PKG),
respectively, have both been shown to inhibit adhesion
and spreading on fibrinogen and platelet cytoskeletal rear-
rangements [40,41]. Agonists for the other PPAR recep-
tors, PPARa and PPARb/d, have also been shown to
inhibit platelets through increasing cAMP levels [17,42].
To determine whether PPARc agonists achieve inhibition
of aIIbb3 through the up-regulation of cyclic nucleotide
signaling, the effect of PPARc agonists 15dPGJ2 and
ciglitazone on cGMP and cAMP signaling was deter-
mined.
Resting human washed platelets were treated with
15dPGJ2 (10, 20 lM) for 10 min prior to lysis (resting
samples) or adhesion to fibrinogen (100 lg mL1). The
samples were then analyzed for VASP phosphorylation
at Ser239, which is the PKG selective phosphorylation
site. Interestingly, although no alteration of VASP S239
phosphorylation was observed in resting platelets
(Fig. 4A) an increase in VASP S239 was observed in fib-
rinogen-adhered (100 lg mL1) platelets (Fig. 4B) fol-
lowing treatment with 15dPGJ2. This suggested that in
fibrinogen-activated platelets PKG activity is increased
following treatment with 15dPGJ2. This increase in
VASP S239 phosphorylation in fibrinogen-adhered plate-
lets was not prevented following treatment with the
PKG inhibitor (Rp-8-Br-PET-cGMPS) (30 lM) at a con-
centration that was capable of reversing NO donor
PAPA-Nonoate (100 lM) mediated increases in VASP
S239, thereby suggesting the increase in VASP S239
phosphorylation is independent of PKG activity
(Fig. 4C).
It has been previously described that PKA can be
responsible for phosphorylation of VASP at S239 [43].
The PKA signaling cascade has also been shown to nega-
tively regulate platelet shape change and spreading
through regulation of RhoA [40]. The ability of PPARc
agonists to alter PKA activity was therefore determined.
As shown in Fig. 5(A, B), treatment with 15dPGJ2
caused a significant increase (8–10-fold following treat-
ment with 20 lM) in VASP S157 phosphorylation in both
resting and fibrinogen-adhered platelets compared with
vehicle alone. This increase in VASP S157 phosphoryla-
tion was also observed in ciglitazone-treated platelets
(Figure S3C) and correlated with concentrations of
15dPGJ2 that caused a reduction in MLC S19, b3 Y773
phosphorylation and other integrin aIIbb3 outside-signal-
ing components (Figs 2 and 3).
PPARc agonists up-regulate PKA activity
Pretreatment with PKA inhibitors H89 (10 lM) or Rp-8-
CPT-cAMPs (100 lM) reduced both 15dPGJ2 and ciglita-
zone-mediated increases in VASP S157 phosphorylation
in resting and fibrinogen-adhered platelets (Fig. 5A,B and
Figure S3C), supporting our hypothesis that the increase
in VASP S157 phosphorylation following treatment with
either PPARc agonist is a result of an increase in PKA
activity (Fig. 5A,B).
In addition to PKA, VASP has also been shown to be
phosphorylated in platelets by the classical PKC isoforms
following stimulation by both GPVI agonists and throm-
bin [44–46]. PKC activity following treatment of platelets
with 15dPGJ2, however, appeared to be unaffected
because this was not associated with an increase in PKC
substrate phosphorylation (Figure S4A) and treatment
with a pan-PKC inhibitor GF109203X (10 lM) did not
prevent the 15dPGJ2 and ciglitazone-induced increases in
VASP S157 phosphorylation. (Figure S4B and C). VASP
can also be phosphorylated at S157 by AKT, which is
activated downstream of PI3-kinase, although PPARc
agonist-induced increases in VASP S157 phosphorylation
were not prevented following treatment by either the PI3-
kinase inhibitor LY29400 (100 lM) or AKT inhibitor
AKT inhibitor IV (5 lM) (Figure S5), which provides fur-
ther support that the effect of PPARc agonists is a result
of activation of PKA.
Activation of PKA is widely known to occur follow-
ing stimulation of Gs coupled receptors, including the
prostaglandin receptors: the IP, DP and EP receptors
[2]. Although more widely known as an endogenous
ligand of PPARc, 15dPGJ2 has also been identified as a
possible ligand for the DP1 and DP2 receptors. To rule
out that the observed effects were a result of PPARc
ligands activating the prostaglandin receptors, VASP
S157 phosphorylation was measured in 15dPGJ2 (10,
20 lM) and ciglitazone (10, 20 lM)-treated resting plate-
lets in the absence and presence of a DP/EP receptor
antagonist AH6809 (10 lM) [47] and IP receptor antago-
nist Ro1138452 (10 lM) [48,49]. As shown in Figure S6,
at concentrations of AH6809 and Ro1138452 that are
capable of reversing PGD2 and PGI2-mediated inhibi-
tion of platelet function [47,49], no reversal of PPARc
ligand-induced VASP S157 phosphorylation was
observed, suggesting that neither 15dPGJ2 nor ciglita-
zone activates PKA via activation of the prostaglandin
receptors (Figure S6).
Interestingly, and in further support of lack of
involvement of Gs coupled signaling, no apparent alter-
ation in cAMP levels was observed in resting platelets
treated with increasing concentrations of 15dPGJ2
(Fig. 5C), suggesting that the PPARc agonists primarily
regulate platelet activity through the up-regulation of
PKA activity rather than through the alteration of
cAMP levels. Furthermore, treatment of platelets with
the PKA inhibitor H89 but not the adenylyl cyclase
inhibitor SQ22356, reversed 15dPGJ2-induced inhibition
of adhesion to fibrinogen and clot retraction (Fig. 6A
and B). Treatment with H89 also reversed 15dPGJ2-
mediated inhibition of both MLC and b3 phosphoryla-
tion in thrombin- stimulated and fibrinogen-adhered pla-
telets (Fig. 6C and D).
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PPARc ligands inhibit integrin b3 interaction with Ga13
In addition to RhoA, which is located further down-
stream in integrin signaling, Ga13 is hypothesized to be
phosphorylated and regulated by PKA at a site that could
result in conformational changes potentially altering its
interaction with its binding partners, including b3
[2,50,51]. Upon binding of the integrin to fibrinogen,
Ga13 is thought to bind to the cytoplasmic domain of b3
and is considered to be the directional ‘switch’ that initi-
ates outside-in signaling [32,33]. To ascertain whether
PPARc ligands disrupt this interaction, the interaction of
b3 with Ga13 in thrombin-stimulated platelets in the
presence and absence of PPARc ligands was determined.
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b3 was co-immunoprecipitated with Ga13 using an anti-
body raised against Ga13. As expected, an increase in the
amount of co-immunoprecipitated b3 was observed fol-
lowing stimulation with thrombin (0.1 U mL1) com-
pared with resting platelets and this interaction was
significantly reduced following treatment with either
15dPGJ2 or ciglitazone (Fig. 7).
Discussion
Outside-in signaling following fibrinogen binding to
integrin aIIbb3 plays a critical role in platelet function
and normal hemostasis and is a necessary secondary
activation pathway downstream of several platelet ago-
nists, including both GPVI and GPCR agonists [52].
PPARc agonists have been shown to have inhibitory
effects on both GPVI and thrombin-evoked inside-out
signaling and platelet activation [6–8] and it is thought
that the PPARc agonists inhibit GPVI-induced platelet
activation by altering the interaction of PPARc with, and
then phosphorylation of, GPVI signaling proteins, includ-
ing Syk, LAT and PLCc2, proteins that are shared by
integrin aIIbb3 outside-in signaling. We therefore investi-
gated whether PPARc agonists are involved in the
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regulation of outside-in signaling mediated through the
platelet integrin aIIbb3 and hence play a wider role in the
regulation of platelet activation.
Binding of integrin aIIbb3 to and adhesion of platelets
on fibrinogen initiates ‘outside-in’ signaling that leads to
cytoskeletal changes involved in the generation and exten-
sion of filopodia and lamellipodia and platelet spreading
[52]. Agonists for PPARc, including 15dPGJ2, a natural
PPARc agonist, and a synthetic agonist, ciglitazone,
caused an inhibition of both platelet adhesion and spread-
ing on fibrinogen in comparison to vehicle-treated plate-
lets. Clot retraction, another functional process that
requires aIIbb3 outside-in signaling [53], was also inhib-
ited, providing further evidence that PPARc agonists reg-
ulate processes involved in aIIbb3 outside-in signaling.
Studies exploring the effect of 15dPGJ2 on platelet adhe-
sion to collagen or fibrinogen under flow established that
although treatment with 15dPGJ2 reduced platelet adhe-
sion to fibrinogen, 15dPGJ2 does not alter platelet adhe-
sion to collagen, suggesting that earlier observations of
PPARc agonist-induced inhibition of thrombus formation
[7] could be attributed to reduced aIIbb3 outside-in sig-
naling during the later stages of thrombus formation
rather than earlier adhesion events.
Upon binding of the integrin to fibrinogen, the G protein
subunit Ga13 is thought to bind to the cytoplasmic domain
of b3, a process that is enhanced by GPCR signaling
[32,33] and is considered to be the directional ‘switch’ that
initiates outside-in signaling through integrin aIIbb3. This
recruitment of Ga13 to b3 leads to the activation of the Src
family kinases (SFKs), including c-Src, which results in the
SFK-dependent phosphorylation of two tyrosine residues
in the b3 tail, Y747 (Y773 in humans) and Y759, which is
critical for outside-in signaling and interaction with other
signaling and intracellular molecules. Y747 negatively reg-
ulates talin binding and Y759 protects against calpain
cleavage [29–31,33,34,52–54]
In platelets pretreated with the PPARc agonist 15dPGJ2,
a significant reduction in phosphorylation of b3 at Y773
was noted (Fig. 3A), suggesting that the negative regulation
of integrin-aIIbb3-dependent processes occurs because of a
direct negative regulation of the b3 integrin itself. This neg-
ative regulation of b3 signaling by the PPARc agonists is
further supported by attenuation of all downstream signal-
ing (Fig. 3B,C), including phosphorylation and activation
of Syk, PLCc2 and PKC activity, known downstream com-
ponents of one branch of b3-dependent c-Src-activated sig-
naling [25,52,53,55,56], and phosphorylation and activation
of FAK and PI3K, key mediators in the secondary wave of
outside-in signaling [35–38] (Fig. 3D). In addition, RhoA
signaling, which occurs following activation of c-Src and is
required for cytoskeleton rearrangements, cell spreading
and platelet clot retraction [57], was also altered in PPARc
agonist-treated platelets and myosin light chain phosphory-
lation (an effector of RhoA activity) was reduced in
15dPGJ2-treated platelets compared with vehicle controls.
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Global inhibition of aIIbb3 signaling by PPARc ago-
nists suggests negative regulation occurs upstream in the
signaling pathway. However, control of the level of plate-
let activation is the result of a balance of activatory and
inhibitory signaling. Reduction in these activating mark-
ers could also be a result of the up-regulation of endoge-
nous inhibitory signaling pathways. This balance of
inhibitory vs. activating signals controls the ability of the
platelet to respond to platelet agonists.
A role for PPARc agonists in pathways known to inhi-
bit aIIbb3 signaling was also considered. Agonists for
other PPARs, including PPARa and PPARb/d, have been
shown to inhibit platelet activity through increasing
cAMP levels and PKA activity [17,42]. The cAMP and
PKA signaling cascade has been shown to negatively reg-
ulate a number of platelet functions [2,40,58,59], including
intracellular calcium mobilization and phosphorylation of
Ga13 [50,51], which are important mediators of outside-
in signaling. Platelets treated with either 15dPGJ2 or
ciglitazone showed a significant increase in PKA-mediated
VASP S157 phosphorylation that was not associated with
activation of the DP, EP or IP prostaglandin receptors or
an increase in cAMP levels. In support of this, treatment
of platelets with PKA inhibitor H89, but not the adenylyl
cyclase inhibitor SQ22536, rescued the PPARc agonist-
dependent inhibition of platelet adhesion to fibrinogen,
clot retraction and integrin aIIbb3 signaling.
Although the physiological relevance is as yet unclear,
studies have shown that the PKA phosphorylation site of
Ga13 (T203) is a region that could undergo conforma-
tional changes, potentially altering its interaction with its
binding partners, including b3 [2,50,51]. We observed that
treatment of platelets with PPARc agonists caused a
decrease in Ga13 association with b3, which would pre-
vent c-Src-dependent phosphorylation of b3 and dissocia-
tion of talin, attenuating signaling downstream of integrin
aIIbb3 (Figure S7). We hypothesize that this inhibition of
aIIbb3 outside-in signaling could also underlie the
observed inhibition of stable thrombus formation previ-
ously described in vitro and in vivo [7,19].
This study provides further evidence for a role for ago-
nists of nuclear receptors in the negative regulation of
platelet activation and supports previous reports that sug-
gest PPARc agonists are cardio-protective. PPARc ago-
nists, thiazolidinediones, are currently used in the
treatment of diabetes mellitus type 2. As there is an
increased risk of cardiovascular disease associated with
diabetes, treatment with PPARc agonists could comple-
ment the effects of other antiplatelet therapies in reducing
the risk of thrombosis.
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